Alkem Laboratories Limited has announced the launch of NeuCeno (cenobamate), a new oral therapy for the treatment of partial-onset seizures in adult patients. This marks the first time cenobamate is available in India, offering a significant advancement in epilepsy management. NeuCeno provides a unique dual mechanism of action, aiming to improve seizure control for the millions affected by epilepsy.
Alkem Launches NeuCeno for Epilepsy Treatment
Alkem Laboratories Ltd. today announced the launch of NeuCeno (cenobamate) in India, an anti-seizure medication (ASM) designed for the treatment of partial-onset seizures in adult patients. The launch of NeuCeno, available in various strengths including 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg tablets, signifies a major advancement in the management of epilepsy in the country.
Addressing Unmet Needs in Epilepsy Care
Epilepsy affects an estimated 9.4 million people in India, with a considerable number experiencing uncontrolled seizures despite existing treatments. NeuCeno offers a novel therapeutic option, acting through a unique dual mechanism that selectively inhibits persistent sodium current and enhances GABA-A receptor activity. Clinical studies have shown that adjunctive cenobamate can reduce seizure frequency by up to 78%.
Commitment to Patient Care
Commenting on the launch, Sandeep Singh, Managing Director, Alkem Laboratories Limited, stated, “People living with epilepsy and their caregivers face significant challenges in achieving effective seizure control. Cenobamate has the potential to transform treatment outcomes towards delivering better epilepsy management. At Alkem, we believe patients deserve access to advanced treatment options that can help address unmet medical needs.” The company remains committed to providing high-quality, affordable medicines and improving patient care.
About Alkem Laboratories Ltd.
Alkem Laboratories Ltd. is a leading Indian pharmaceutical company with a 50-year legacy, recognized as the sixth-largest pharmaceutical company in the Indian market. The company specializes in anti-infectives, gastrointestinal, and pain management drugs, with a growing portfolio in chronic therapies like diabetes, neurology, and cardiology. Alkem operates 20 state-of-the-art manufacturing facilities and R&D centers across India and the US.
Source: BSE
